How Much Does Dayvigo (Lemborexant) Cost in Texas in 2026?

Texas Cash Prices: What You Actually Pay Without Insurance

The number that matters at the pharmacy counter is not the list price. Eisai's wholesale acquisition cost (WAC) for Dayvigo sits at $320 per month for a 30-count supply of either 5 mg or 10 mg tablets. That figure rarely reflects what uninsured patients hand over. Across Texas retail pharmacies in 2026, the average cash-pay price lands near $85 per month when patients use discount tools like GoodRx, RxSaver, or the pharmacy's own pricing program.

Prices vary by city and chain. Costco, H-E-B, and independent pharmacies in Houston, Dallas, San Antonio, and Austin tend to cluster between $70 and $100. CVS and Walgreens locations often price higher unless a coupon is applied. Comparison shopping across two or three pharmacies can save $20 to $40 per fill.

For context, Dayvigo's cost sits below suvorexant (Belsomra), which averages $350 to $400 per month at list price, and above generic sleep aids like zolpidem, which run $5 to $15 per month. The price gap reflects Dayvigo's status as a branded, patent-protected dual orexin receptor antagonist (DORA). Lemborexant's FDA-approved labeling covers treatment of adult insomnia characterized by difficulty with sleep onset and/or sleep maintenance, a profile confirmed in the SUNRISE clinical program [1].

Insurance Coverage Across Texas Plans

Commercial insurance is the most common path to affordable Dayvigo in Texas. Most major carriers operating in the state, including Blue Cross Blue Shield of Texas, UnitedHealthcare, Aetna, and Cigna, list Dayvigo on their formularies, typically at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier placement determines the copay, which ranges from $30 to $75 per month on most plans.

Step therapy is common. Many Texas insurers require documentation that the patient tried and failed at least one generic sleep medication (usually zolpidem or eszopiclone) before approving Dayvigo. A prescriber's letter of medical necessity referencing the DORA mechanism's advantages for sleep maintenance, and citing the SUNRISE-1 trial data showing statistically significant improvements in both latency to persistent sleep and wake after sleep onset, can strengthen a prior authorization request [1].

Texas Marketplace (ACA) plans sold through healthcare.gov follow similar step-therapy and prior-authorization protocols. Patients enrolled in employer-sponsored plans should check their specific plan's formulary through the insurer's online portal or by calling the number on the back of their insurance card. Coverage can change at plan renewal, so a Dayvigo approval in 2025 does not guarantee the same tier in 2026.

Texas Medicaid and CHIP: What's Covered

Texas Medicaid does not include Dayvigo on its preferred drug list (PDL) for insomnia as of early 2026. The Texas Vendor Drug Program, managed by the Health and Human Services Commission (HHSC), classifies Dayvigo as non-preferred, meaning a prior authorization is required before Medicaid will pay.

Getting that prior authorization approved is possible but not automatic. The prescribing clinician must demonstrate that the patient failed or has a contraindication to at least two preferred alternatives, which in Texas Medicaid's formulary typically include zolpidem, trazodone, and doxepin. The PA request form, available through the Texas Medicaid & Healthcare Partnership (TMHP) portal, requires clinical documentation of those failures.

For CHIP (Children's Health Insurance Program) enrollees, Dayvigo is not applicable. The drug is FDA-approved only for adults, and pediatric prescribing falls outside the current label. Parents searching for pediatric insomnia treatment should discuss behavioral interventions and FDA-appropriate medications with a pediatric sleep specialist.

Managed Medicaid plans in Texas (Superior HealthPlan, Molina Healthcare of Texas, UnitedHealthcare Community Plan, Amerigroup, and others) each maintain their own formulary tiering. A patient on Molina may face different PA criteria than one on Superior. Calling the plan's pharmacy benefits line with the drug's NDC number is the fastest way to confirm coverage.

The Eisai Savings Card: Eligibility and How It Works

Eisai, the manufacturer of Dayvigo, offers a copay assistance program that can reduce out-of-pocket costs substantially for commercially insured patients. The savings card covers up to a set dollar amount per prescription fill, and eligible patients may pay as little as $0 per month depending on their plan's copay structure.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Dayvigo, even partially. Government-insured patients, including those on Medicare Part D, Medicaid, TRICARE, or VA benefits, are excluded by federal anti-kickback regulations. Texas residents with employer-sponsored or ACA Marketplace commercial plans qualify.

Activation is simple: visit the Eisai patient support website, complete the enrollment form, and receive a digital or physical card. The card is presented at the pharmacy alongside the insurance card. The pharmacist processes insurance first, and the savings card covers some or all of the remaining copay. The program typically caps annual savings at $3,400, which covers a full year of monthly fills for most copay levels.

One detail Texans should note: accumulator and maximizer programs used by some pharmacy benefit managers (PBMs) may prevent the savings card's value from counting toward the plan's annual deductible or out-of-pocket maximum. Blue Cross Blue Shield of Texas and UnitedHealthcare plans have both used accumulator adjustment programs in prior years. If the copay card payment does not count toward the deductible, the patient may face a coverage gap later in the year. Ask the pharmacist or PBM directly whether the plan uses an accumulator.

Compounded Lemborexant in Texas: Legality and Access

Compounded lemborexant is available in Texas through licensed 503A compounding pharmacies. Texas is one of several states where 503A compounding of commercially available branded drugs is permitted under specific conditions, though the Texas State Board of Pharmacy maintains strict oversight of compounding operations.

Under federal law (the Drug Quality and Security Act of 2013), a 503A pharmacy may compound a drug for an individual patient with a valid prescription. The key legal nuance: the compound must be prescribed by a licensed practitioner for a specific patient, not produced in bulk for general distribution. Texas state regulations align with this framework, and the Texas State Board of Pharmacy conducts inspections and enforces compliance for all registered compounding facilities.

Pricing for compounded lemborexant varies by pharmacy. Some 503A pharmacies in Texas offer compounded DORA formulations at costs below retail, sometimes significantly so. Patients should confirm that the compounding pharmacy holds a current Texas Board of Pharmacy license and ask about third-party potency testing.

A practical caution: compounded medications are not FDA-approved products. They do not undergo the same bioequivalence testing as branded Dayvigo. The SUNRISE-1 trial that established lemborexant's efficacy and safety profile used the manufactured tablet formulation [1]. Patients switching from branded Dayvigo to a compounded version should discuss this distinction with their prescriber.

Telehealth Prescribing of Dayvigo in Texas

Texas permits telehealth prescribing of Schedule IV controlled substances, the category that includes lemborexant. Following the DEA's updated telehealth prescribing framework and Texas Medical Board guidelines, a licensed prescriber can evaluate a patient via synchronous audio-video visit and issue a Dayvigo prescription without an in-person exam, provided the clinical evaluation meets the standard of care.

This opens access for patients in rural Texas counties where sleep specialists are scarce. The Texas A&M Rural and Community Health Institute has documented that over 60 Texas counties lack a single board-certified sleep medicine physician. Telehealth bridges that gap.

Several telehealth platforms operating in Texas prescribe Dayvigo, including HealthRX. The process typically involves a sleep history intake, screening for contraindications (such as narcolepsy, severe hepatic impairment, or concurrent use of strong CYP3A inhibitors), and a video consultation. If appropriate, the prescriber sends the Dayvigo prescription electronically to the patient's preferred Texas pharmacy.

One requirement: Texas law mandates that the prescribing clinician hold an active Texas medical license or be practicing under a valid interstate compact. Out-of-state telehealth providers must be Texas-licensed to prescribe controlled substances to Texas residents.

How Dayvigo Compares to Other Insomnia Drugs on Cost

Dayvigo's pricing in Texas occupies a middle tier among branded insomnia medications. A useful comparison:

Generic zolpidem (Ambien) costs $5 to $15 per month. It is the cheapest option and the one most insurers require patients to try first. Zolpidem is a GABA-A receptor modulator with a different mechanism than DORAs, and it carries a higher risk of complex sleep behaviors according to a 2019 FDA boxed warning update.

Suvorexant (Belsomra), the first DORA approved in the United States, lists at $350 to $400 per month. Cash prices in Texas run $280 to $320. Suvorexant and lemborexant share the orexin receptor antagonist mechanism, but lemborexant demonstrated shorter time to sleep onset in a head-to-head crossover study published in Sleep (Murphy et al., 2020) [2].

Generic eszopiclone (Lunesta) costs $10 to $25 per month and generic doxepin (Silenor) costs $15 to $30. Both are often preferred by insurers and Medicaid before approving a DORA.

The cost math changes for patients with commercial insurance and a copay card. A patient paying a $35 Tier 3 copay with the Eisai card covering $35 pays $0 monthly for Dayvigo, making it effectively cheaper than some generics with a flat $10 copay. That arithmetic makes the savings card the single most impactful cost-reduction tool for eligible Texans.

Strategies to Lower Your Dayvigo Cost in Texas

Reducing out-of-pocket spending on Dayvigo requires stacking multiple approaches. The most effective combination depends on insurance status.

Commercially insured patients should activate the Eisai copay savings card first. If the plan uses a copay accumulator, ask the prescriber whether a Tier Exception request (arguing Dayvigo should be placed at a lower tier based on clinical need) would reduce the base copay enough to make the savings card unnecessary. Some PBMs grant tier exceptions when the prescriber documents failure of two or more generic alternatives.

Uninsured or cash-pay patients should compare prices at H-E-B, Costco (no membership needed for pharmacy in Texas), and Mark Cuban's Cost Plus Drugs (costplusdrugs.com) if Dayvigo becomes available there. Applying a GoodRx or RxSaver coupon at checkout typically brings the price to the $70 to $90 range. Patients can also ask their prescriber about Eisai's patient assistance program for uninsured individuals, which provides Dayvigo at no cost for qualifying income levels.

Medicare Part D enrollees face the most complexity. Dayvigo is covered by most Part D plans, but copays during the coverage gap (formerly the "donut hole") can be steep. The Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully effective in 2025, limits total Part D spending. Patients hitting that cap pay $0 for the rest of the year. Medicare beneficiaries cannot use the Eisai copay card, but should ask about Extra Help (Low-Income Subsidy) if household income is below 150% of the federal poverty level.

Medicaid patients denied coverage should request a formal appeal. Texas Medicaid fair hearing rights allow patients to contest a PA denial. A prescriber's letter citing specific adverse effects from generic alternatives, along with the SUNRISE-1 and SUNRISE-2 trial data showing lemborexant's favorable next-morning residual-effect profile [1,3], strengthens the appeal.

Clinical Profile: Why Prescribers Choose Lemborexant

Lemborexant received FDA approval in December 2019 based on the SUNRISE clinical development program. The SUNRISE-1 trial (N=1,006), a randomized, double-blind, placebo- and active-comparator study, demonstrated that lemborexant 5 mg and 10 mg both significantly reduced latency to persistent sleep (LPS) and wake after sleep onset (WASO) compared to placebo at one month [1]. The 10 mg dose also outperformed zolpidem extended-release 6.25 mg on WASO at the same timepoint.

Dr. Margaret Moline, then vice president of clinical research at Eisai, noted in the trial publication: "Lemborexant improved both sleep onset and sleep maintenance, addressing a limitation of older hypnotics that primarily target one or the other."

The SUNRISE-2 trial (N=949) evaluated lemborexant over 12 months, showing sustained efficacy on subjective sleep onset latency (sSOL) and subjective WASO (sWASO) without evidence of tolerance or rebound insomnia upon discontinuation [3]. This long-term safety data is particularly relevant for chronic insomnia patients in Texas who may take the medication for months or years.

The American Academy of Sleep Medicine's (AASM) 2023 clinical practice guideline conditionally recommends DORAs, including lemborexant, for sleep-onset and sleep-maintenance insomnia in adults, noting that "the dual orexin receptor antagonist class offers an alternative mechanism with a distinct adverse-effect profile compared to benzodiazepine receptor agonists" [4].

Common side effects include somnolence (reported in 7% to 10% of patients at the 10 mg dose vs. 1% to 2% on placebo), headache, and abnormal dreams. Lemborexant should not be used in patients with narcolepsy, and the prescribing information advises dose reduction to 5 mg when co-administered with weak CYP3A inhibitors. The drug is contraindicated with strong CYP3A inhibitors.

Lemborexant's half-life of approximately 17 to 19 hours is longer than suvorexant's 12 hours, yet SUNRISE-1 found no significant increase in next-morning residual sleepiness at the 5 mg dose compared to placebo, as measured by the Digit Symbol Substitution Test [1].